Table 2.
Hemodynamic effects of SERCA2a overexpression after 2–3 days
| Treatment | HR, min−1 | LVSP, mm Hg | +dP/dt, mm Hg/sec | −dP/dt, mm Hg/sec | LVEDP, mm Hg | τ, msec |
|---|---|---|---|---|---|---|
| Control Sham | 348 ± 76 | 95 ± 13 | 6,929 ± 1,353 | −5,967 ± 1,594 | 4 ± 3 | 20 ± 3 |
| Sham + Ad.βgal | 363 ± 41 | 91 ± 11 | 6,909 ± 2,020 | −5,572 ± 1,227 | 4 ± 3 | 19 ± 4 |
| Failing + Ad.βgal | 453 ± 35† | 129 ± 20† | 4,830 ± 1,497† | −3,813 ± 1,567† | 9 ± 5† | 23 ± 7† |
| Sham + SERCA2a | 357 ± 36 | 97 ± 10 | 8,438 ± 1,770† | −6,452 ± 1,553† | 6 ± 3 | 13 ± 4 |
| Failing + SERCA2a | 420 ± 42*† | 165 ± 27*† | 7,332 ± 2,584* | −6,110 ± 1,711* | 11 ± 9 | 14 ± 3*† |
HR, heart rate; LVSP, left-ventricular systolic pressure; +dP/dt, maximal rate of rise of left-ventricular pressure; −dP/dt, maximal rate of decline of left-ventricular pressure; LVEDP, left-ventricular end-diastolic pressure; τ, time course of isovolumic relaxation; *, P < 0.05 compared to Failing + Ad.βgal; †, P < 0.05 compared to Sham + Ad.βgal.